Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide in Partial Lipodystrophy
NCT03262610Phase 2Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Aug 2017
- Primary completion
- Jan 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of setmelanotide in partial lipodystrophy, sponsored by Rhythm Pharmaceuticals. Started Aug 2017; status: completed.
02
Drugs
setmelanotide
03
Conditions
partial lipodystrophy
Beyond the preview
Go deeper on NCT03262610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03262610.